secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097577
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Phase 3 X-TOLE2 azetukalner meets primary endpoint; NDA submission Q3 2026
--------------------------------------------------------------------------------

- Primary endpoint MPC: 25mg -53.2% vs placebo -10.4% (p<0.000000000006); placebo-adjusted -42.7%, outperforming Phase 2b.
- Key secondary RR50: 54.8% (25mg) vs 20.8% placebo (p=0.00000008).
- Safety consistent: most common TEAEs dizziness (20.5%), headache (8.8%), somnolence (8.8%), fatigue (7.6%).
- NDA submission to FDA planned Q3 2026 for focal onset seizures.
- Data to be presented as Late Breaking Science at AAN Annual Meeting in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526097577/0001193125-26-097577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526097577/d107087d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer